I
Intellia Therapeutics, Inc. (NTLA)
NGM – Real vaqt narxi. Valyuta: USD
13.99
-0.43 (-2.98%)
Yopilishda: May 12, 2026, 4:00 PM EDT
14.00
+0.01 (0.06%)
Bozordan keyin: May 12, 2026, 7:52 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
13.99
-0.43 (-2.98%)
Yopilishda: May 12, 2026, 4:00 PM EDT
14.00
+0.01 (0.06%)
Bozordan keyin: May 12, 2026, 7:52 PM EDT
Intellia Therapeutics, Inc. CRISPR/Cas9 texnologiyalaridan foydalangan holda potentsial davolovchi terapiyalarni ishlab chiqishga qaratilgan klinik bosqichdagi gen tahrirlash kompaniyasidir. Kompaniya gen tahrirlash uchun klasterlangan, muntazam ravishda joylashtirilgan qisqa palindromik takrorlar ("CRISPR") / CRISPR bilan bog'liq 9 ("Cas9") texnologiyasini taklif etadi. Kompaniya kasalliklar uchun in vivo va ex vivo terapiyalarni rivojlantirish uchun modulli platformani taqdim etadi. Kompaniyaning in vivo mahsulot nomzodlari transtiretin amiloidozini davolash uchun nexiguran ziklumeran yoki NTLA-2001; va irsiy angionevrotik shishni davolash uchun NTLA-2002 ni o'z ichiga oladi. Bundan tashqari, u immuno-onkologiya va autoimmün kasalliklarni davolash uchun mahsulot nomzodlarini va jigardan tashqari organlarga gen tahrirlash terapiyalarini etkazib berish orqali sezilarli tibbiy ehtiyojlari bo'lgan kasalliklarni davolash uchun bir nechta in vivo dasturlarni taklif etadi. Kompaniya AvenCell Therapeutics, Inc. bilan allogen universal CAR-T hujayrali terapiyalarini ishlab chiqish uchun; Kyverna Therapeutics, Inc. bilan turli xil B-hujayrali autoimmün kasalliklarni davolash uchun allogen CD19 CAR-T hujayrali terapiyasini ishlab chiqish uchun; ONK Therapeutics, Ltd. bilan saraton bilan og'rigan bemorlarni davolash uchun muhandislik NK hujayrali terapiyalarini ishlab chiqish uchun; va ReCode Therapeutics, Inc. bilan siydik fibrozini davolash uchun yangi genetik dorilarni ishlab chiqish uchun litsenziya va hamkorlik shartnomasiga ega. Shuningdek, u Regeneron Pharmaceuticals, Inc., SparingVision SAS va Rewrite Therapeutics Inc. bilan hamkorlik shartnomalariga ega. Kompaniya ilgari AZRN, Inc. nomi bilan tanilgan va 2014 yil iyul oyida Intellia Therapeutics, Inc. nomini o'zgartirgan. Intellia Therapeutics, Inc. 2014 yilda tashkil etilgan va shtab-kvartirasi Kembrijda, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Birgit Schultes Ph.D. | Executive VP & Chief Scientific Officer |
| Dr. David Lebwohl M.D. | Executive VP & Chief Medical Officer |
| Dr. Derrick J. Rossi Ph.D. | Founder & Member of Scientific Advisor Board |
| Dr. Jennifer A. Doudna Ph.D. | Founder & Member of Scientific Advisor Board |
| Dr. John M. Leonard M.D. | President, CEO & Director |
| Dr. Rachel E. Haurwitz Ph.D. | Co-Founder |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-11 | 8-K | ntla-20260511.htm |
| 2026-05-11 | 10-Q | ntla-20260331.htm |
| 2026-04-30 | DEF 14A | ntla-20260430.htm |
| 2026-04-30 | 8-K | d308328d8k.htm |
| 2026-04-27 | 8-K | d138980d8k.htm |
| 2026-04-10 | 8-K | d65395d8k.htm |
| 2026-03-02 | 8-K | d101756d8k.htm |
| 2026-02-26 | S-8 | d119130ds8.htm |
| 2026-02-26 | 8-K | ntla-20260226.htm |
| 2026-01-27 | 8-K | d29201d8k.htm |
| Dr. Rodolphe Barrangou M.B.A., Ph.D. | Founder & Member of Scientific Advisor Board |
| Mr. Edward J. Dulac III | Executive VP, CFO & Treasurer |
| Mr. James E. Basta Esq., J.D. | Executive VP, General Counsel & Corporate Secretary |
| Prof. Luciano Marraffini Ph.D. | Founder & Member of Scientific Advisor Board |